LIGHTPATH TECHNOLOGIES INC
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
LPTH$7.99-0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows
| Nine Months Ended | ||
|---|---|---|
| March 31, | ||
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(16,404,698) | $(7,817,202) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 3,717,691 | 3,356,752 |
| Interest from amortization of loan issuance costs | 90,124 | 161,905 |
| Amortization of fair value of loan | 90,321 | — |
| Loss on extinguishment of debt | 506,280 | 418,502 |
| Change in fair value of warrant liability | — | (870,554) |
| Change in fair value of acquisition earnout liabilities | 12,234,529 | 130,445 |
| Earnout payment for acquisition of G5, net of financing portion | (3,813,587) | — |
| Loss on disposal of property and equipment | 4,016 | 80,505 |
| Stock-based compensation on stock options, RSUs & RSAs, net | 1,261,577 | 745,155 |
| Provision for credit losses | (26,034) | (3,014) |
| Change in operating lease assets and liabilities | (181,814) | (91,582) |
| Inventory write-offs to allowance | 215,129 | 135,625 |
| Deferred taxes | (64,323) | (2,368) |
| Changes in operating assets and liabilities, net of acquisitions: | ||
| Trade accounts receivable | (1,200,965) | (822,043) |
| Other current assets | (145,353) | 73,362 |
| Inventories | (247,597) | (1,206,340) |
| Prepaid expenses and deposits | (2,182,257) | (360,439) |
| Accounts payable and accrued liabilities | 1,030,382 | 389,844 |
| Net cash used in operating activities | (5,116,579) | (5,681,447) |
| Cash flows from investing activities: | ||
| Purchase of property and equipment | (1,844,395) | (580,726) |
| Proceeds from sale of equipment | — | 10,648 |
| Acquisition of Amorphous | (7,000,111) | — |
| Acquisition of G5 | — | (20,250,011) |
| Net cash used in investing activities | (8,844,506) | (20,820,089) |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options | 12,503 | 3,175 |
| Proceeds from sale of common stock from Employee Stock Purchase Plan | 24,862 | 14,385 |
| Proceeds from issuance of common stock under public equity placement, net of fees | 65,242,541 | — |
| Proceeds from issuance of common stock under private equity placement, net of fees | 7,894,045 | 437,725 |
| Proceeds from issuance of preferred stock under private equity placement, net of fees | — | 18,842,138 |
| Proceeds from issuance of warrants under private equity placement, net of fees | — | 4,620,561 |
| Earnout payment for acquisition of G5, net of operating portion | (3,536,471) | — |
| Deferred payment for acquisition of Visimid | — | (125,000) |
| Borrowings on loans payable | — | 6,659,596 |
| Loan issuance costs | — | (597,465) |
| Payments on loans payable | (5,442,930) | (149,118) |
| Repayment of finance lease obligations | (168,089) | (133,711) |
| Net cash provided by financing activities | 64,026,461 | 29,572,286 |
| Effect of exchange rate on cash and cash equivalents | 292,769 | (72,133) |
| Change in cash and cash equivalents | 50,358,145 | 2,998,617 |
| Cash and cash equivalents, beginning of period | 4,877,036 | 3,480,268 |
| Cash and cash equivalents, end of period | $55,235,181 | $6,478,885 |
| Supplemental disclosure of cash flow information: | ||
| Interest paid in cash | $390,457 | $66,136 |
| Income taxes paid | $194,527 | $118,016 |
| Supplemental disclosure of non-cash investing & financing activities: | ||
| Purchase of equipment through finance lease arrangements | $275,471 | $93,048 |
| Operating right-of-use assets acquired in exchange for operating lease liabilities | $1,956,911 | $— |
| Issuance of common stock for acquisition of Visimid | $350,000 | $713,946 |
| Issuance of common stock for acquisition of G5, including earnouts | $3,149,942 | $4,872,068 |
| Issuance of common stock for acquisition of AML, including earnouts | $1,027,080 | $— |
| Accrual of earnout consideration for acquisition of G5 | $— | $3,536,471 |
| Accrual of earnout consideration for acquisition of AML | $1,780,000 | $— |
| Extinguishment of debt in exchange for common stock, preferred stock, warrants and a note | $— | $3,057,110 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.